Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box protein D2 (FOXD2) is a member of the evolutionarily conserved forkhead family of transcription factors, defined by a forkhead DNA-binding domain. FOXD2 modulates developmental processes and intracellular signaling, especially in neural and mesoderm tissues, and plays a critical role in T cell activation by regulating components of the cAMP-dependent protein kinase pathway. In human colorectal cancer, FOXD2 functions as a chromatin-tuning factor; it remodels enhancer–promoter interactions and recruits MLL4/KMT2D, thereby inducing H3K4 monomethylation that triggers apoptosis through p53-responsive genes and suppresses tumor growth. FOXD2 dysregulation is linked to various cancers and is proposed as a tumor suppressor, while non-coding RNAs transcribed from the FOXD2 locus (e.g., FOXD2-AS1) act as oncogenic drivers and prognostic biomarkers in multiple tumor types.
As a transcription factor, FOXD2 modulates enhancer/promoter interactions and recruits MLL4/KMT2D, leading to H3K4 monomethylation, chromatin opening, and activation of tumor suppressor genes and apoptosis pathways, especially p53-responsive genes in colorectal cancer
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Forkhead box protein D2 (FOXD2).